Seeking Alpha

CarolinaCowboy

CarolinaCowboy
Send Message
View as an RSS Feed
View CarolinaCowboy's Comments BY TICKER:
Latest  |  Highest rated
  • An End To Our Relationship With Yahoo, A New Era For Equity Research [View article]
    The ONLY time I read S/A was when there was an article under one of my watchlists on Yahoo finance so I doubt I will be seeing the articles much any more. Now, most likely only if a link is provided from a poster on another forum.

    I never did care for the fact that short sellers were writing the hit articles for their own gain anyway. It's no loss to me.
    Aug 3 10:07 AM | 1 Like Like |Link to Comment
  • Any Hopes Left For Amarin Bulls? [View article]
    chris2468, Exactly! For the author to state "This will enable the company to develop a more efficient version of Vascepa for treating high TG patients", shows he has no clue what Vascepa is. The safety & efficacy of Vascepa were not the issue. Hence, "Amarin has done everything asked of them".
    Dec 3 07:43 PM | 1 Like Like |Link to Comment
  • Any Hopes Left For Amarin Bulls? [View article]
    "This will enable the company to develop a more efficient version of Vascepa for treating high TG patients."
    A more efficient version? What are you talking about?
    Dec 1 08:52 AM | 5 Likes Like |Link to Comment
  • New Study: EPA Reduces Cardiovascular Events - Enough For Amarin Approval? [View article]
    Maybe the panel wouldnt have found the study but AMRN should have!
    Oct 21 11:06 AM | 8 Likes Like |Link to Comment
  • Thoughts On Befuddled FDA AdCom  [View instapost]
    This seems to be exactly what that female panel member was pointing out when she wanted clarification on the voting question. She wanted the vote on the intended SPA, not on the future outcome of the additional R-IT trial. She KNEW that AMRN accomplished exactly what it was asked to do.
    What a fiasco, a sham, this entire thing is.
    By this ruling, ALL trig lowering drugs should be pulled (since they have not been asked to show their burden of proof of CVE) AND they all have safety issues.
    It makes one tend to ask, why bother tracking your trigs at all if this is the logic of the FDA.
    A downright shameful event.
    Oct 17 11:30 AM | 1 Like Like |Link to Comment
  • A Stock That May Rally $20 In 3-Months [View instapost]
    Great article. Thank you.
    Sep 30 11:50 AM | 1 Like Like |Link to Comment
  • Amarin Initiated With BUY At Suntrust $15PT [View instapost]
    I know a bunch of us are hoping you are right, Steve. Hanging in there, CC
    Sep 13 06:28 PM | Likes Like |Link to Comment
  • Yet More New Developmetn Re; Amarin [View instapost]
    Yes, thank you for the update Steve. Any tidbits helps holding these longs.
    Aug 22 12:08 PM | Likes Like |Link to Comment
  • The Future Of Omega-3 Based Lipid Management: All Eyes On Amarin [View article]
    Excellent article. Most informative one yet.
    May 31 09:54 AM | 1 Like Like |Link to Comment
  • AstraZeneca's (AZN -1.5%) $443M deal to acquire Omthera puts the U.K. company at "distinct commercial advantage" over Amarin (AMRN +0.3%), says Decision Resources' Paramjit Narang. Omthera's Epanova drug "offers higher and more constant bioavailability, and arguably better efficacy" in lowering triglyceride than Amarin's Vascepa, and it "lacks the gastrointestinal side effects of the market incumbent Lovaza," which is sold by GSK (GSK -2%). Narang reckons Epanova's annual sales could peak at $1B. [View news story]
    you are quoting "says Decision Resources' Paramjit Narang". Never heard of either of them. Get a REAL source. Do a little homework. LOL
    May 29 10:47 AM | 3 Likes Like |Link to Comment
  • AstraZeneca's (AZN -1.5%) $443M deal to acquire Omthera puts the U.K. company at "distinct commercial advantage" over Amarin (AMRN +0.3%), says Decision Resources' Paramjit Narang. Omthera's Epanova drug "offers higher and more constant bioavailability, and arguably better efficacy" in lowering triglyceride than Amarin's Vascepa, and it "lacks the gastrointestinal side effects of the market incumbent Lovaza," which is sold by GSK (GSK -2%). Narang reckons Epanova's annual sales could peak at $1B. [View news story]
    These are the FACTS as quoted by Joe Z.
    1. Epanova ANCHOR data was worse than their MARINE equivalent data.
    2. On LDL, Epanova increased statistically significant 5% at the 2 gram dose, and at 1% sales and non-inferiority study, this is on their ANCHOR equivalent study.
    3. Vascepa reduced by 6%, a statistically significance. This is going to be a real problem for them.
    4. Lovaza results were better than Epanova yet even Lovaza failed to get their indication approved.
    5 Epanova non-HDL lowering is 1/3 to 1/2 of what Vascepa is doing. They continue to talk about 5% to 7% dropout in their study just due to side effects. Vascepa had 0% in their MARINE study, and had 2% in our ANCHOR study, which was less than placebo.
    6. They got lower Lp-PLA2 results and actually increase Apo B, whereas Vascepa decrease it.
    May 29 10:17 AM | 4 Likes Like |Link to Comment
  • All Eyes Now Focusing On Acquisition Of Amarin [View instapost]
    Didnt GSK get fined for promoting off-label use? AMRN too smart to openly do that. IF Summer Street is short as suggested below, this off-label use sounds like a set-up question to highlight something,anything, negative.
    So far though, AMRN has been a hard pill to swallow. Longs taking one heck of a beating. Hasnt been an easy hold, that's for sure.
    May 28 11:37 AM | 1 Like Like |Link to Comment
  • Amarin's SNDA For Anchor WILL BE APPROVED ON TIME, PERIOD [View instapost]
    Welcome back Steve! Thanks for setting AF straight!
    May 24 02:47 PM | 3 Likes Like |Link to Comment
  • Amarin: It's The Strategy, Not The Science [View article]
    Another clueless article with an author that has not done his homework. #SICKOFTHEM

    Thx for the comments, JL
    May 20 05:07 PM | 2 Likes Like |Link to Comment
  • UniPixel Shares Take One On The Chin [View article]
    If you understood what the AAPL patent was, it would NOT be a concern. This is an excellent read: http://on.barrons.com/...
    May 20 08:15 AM | 3 Likes Like |Link to Comment
COMMENTS STATS
29 Comments
68 Likes